Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 4Carcinoma, Ovarian Epithelial 3Platinum-Sensitive Ovarian Cancer in First Relapse 1Pituitary Neoplasms 1Peritoneal Neoplasms 1Neoplasms 1Fallopian Tube Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Paclitaxel 32Carboplatin 23liposomal doxorubicin 14pembrolizumab 12Topotecan 10Bevacizumab 10Gemcitabine 9mirvetuximab soravtansine 8olaparib 6Cisplatin 61-dodecylpyridoxal 6rucaparib 5Nivolumab 5Cyclophosphamide 5oregovomab 4farletuzumab 3catumaxomab 3Standard of Care 3Irinotecan 3Fulvestrant 3CCV-AV protocol 3talazoparib 2sacituzumab govitecan 2ribociclib 2phenoxodiol 2pegfilgrastim 2pazopanib 2palbociclib 2niraparib 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Ovarian Epithelial × farletuzumab × Clear all
NCT01018563 2021-12-08

An Open Label Extension Study of the Efficacy of MORAb-003

Morphotek

Phase 2 Terminated
3 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial

NCT01004380 2014-07-17

Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

Morphotek

Phase 1 Completed
15 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00428766 2013-11-06

Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer

Morphotek

Phase 1 Completed
24 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡